PetMed Express, Inc.
2.5700-0.09 (-3.38%)
Oct 28, 4:00:00 PM EDT · NasdaqGS · PETS · USD
Key Stats
Market Cap
54.01MP/E (TTM)
-Basic EPS (TTM)
-0.30Dividend Yield
0%Recent Filings
8-K
LaCamp joins PetMed board
PetMed Express appointed James LaCamp, a seasoned finance executive and audit expert, to its board on October 19, 2025, with him assuming the Audit Committee chair role on October 30. This bolsters financial oversight amid board refreshment, now featuring five independent directors since 2024. The company also formalized an interim employment agreement with CEO Leslie C.G. Campbell on October 20, setting her base salary at $1.3 million through August 2026, while retaining at-will termination. LaCamp's expertise sharpens governance; yet integration risks linger.
10-K
FY2025 results
PetMed Express's FY2025 results showed sales declining 17.2% y/y to $227.0M, driven by strategic advertising cuts and macroeconomic pressures, with reorder sales down 15.5% to $188.0M and new orders falling 25.5% to $31.1M; Q4 momentum faltered as recurring sales hit 56.1% of total, up from 53.5% y/y but flat sequentially, amid higher discount activity compressing gross margins to 30.5% from 30.9%. General and administrative expenses dropped 30.0% to $38.6M, fueled by an $8.7M non-cash stock compensation reversal from executive departures, yet operating loss widened to $1.5M from $8.2M, with net loss narrowing to $6.3M via lower advertising spend. Liquidity held firm at $54.7M cash with no debt, supporting $5.1M capex; dividends remain suspended to fund growth. Q4 faltered on prescription sales weakness, but AutoShip adoption signals retention strength. Regulatory scrutiny over pharmacy licensing could disrupt quarterly momentum.
8-K
PetMed files delayed 10-K
PetMed Express filed its delayed Form 10-K on October 14, 2025, revealing fiscal 2025 net sales of $227.0 million and a $6.3 million net loss, dragged by a $1.2 million intangible impairment. Sales missed preliminary estimates due to reclassifying promotional reimbursements to costs, yet net income stayed unaffected. Cash stands at $54.7 million with no debt. Interim CEO eyes resumed quarterly filings soon.
8-K
Impairment and restatement hit PetMed
PetMed Express disclosed a $1.2 million non-cash impairment on its PCRX trade name from the 2023 PetCareRx acquisition, triggered by lower revenues, to be recorded in Q4 fiscal 2025. The company also announced that prior financials from fiscal 2023-2025 require restatement for misclassifying $9.0 million in vendor reimbursements as revenue instead of cost reductions in 2023 and $7.0 million in 2024, with no effect on net income or cash flows. An Audit Committee probe uncovered revenue acceleration errors totaling $1.2 million and control lapses, prompting CEO and CFO resignations. Material weaknesses in internal controls loom large.
8-K
Interim CEO salary approved
PetMed Express's board set an initial $550,000 annual base salary for Interim CEO and President Leslie C.G. Campbell, effective from her August 11, 2025 start, pending a formal agreement; she receives standard senior executive benefits. Separately, Chief Accounting Officer Douglas Krulik, also Interim Principal Financial Officer, earned 10,000 restricted shares on September 9, 2025, vesting fully after six months or upon termination without cause. This bolsters interim leadership stability amid transition.
IPO
Website
Employees
Sector
Industry
CHWY
Chewy, Inc.
34.16-0.45
GDRX
GoodRx Holdings, Inc.
3.66-0.11
HIMS
Hims & Hers Health, Inc.
47.12-1.11
IVP
Inspire Veterinary Partners, In
0.87-0.01
PETV
PetVivo Holdings Inc.
1.49-0.01
PMHS
Polomar Health Services, Inc.
0.20+0.00
PTPI
Petros Pharmaceuticals, Inc.
0.02+0.00
WGRX
Wellgistics Health, Inc.
0.65-0.17
WOOF
Petco Health and Wellness Compa
3.62-0.20
ZTS
Zoetis Inc.
145.41-2.12